• AERO2.46+0.00 +0.00%
  • AGTK0.0114-0.0012 -9.5238%
  • AMMJ0.64-0.06 -8.52%
  • ATTBF0.1558-0.0032 -2.0126%
  • CANN1.20-0.04 -3.23%
  • CARA12.43+0.06 +0.49%
  • CBDS2.83-0.12 -4.07%
  • CGRW0.86565+0.00565 +0.65697%
  • CNAB0.69-0.03 -4.17%
  • DIDG0.0001+0.0000 +0.0000%
  • EDXC0.05165-0.00035 -0.67308%
  • FULL2.67+0.00 +0.00%
  • GBLX0.225-0.005 -2.174%
  • GRNH0.033-0.003 -7.042%
  • GWPH107.63-1.77 -1.62%
  • HEMP0.01965-0.00035 -1.75000%
  • INCC0.0004+0.0001 +33.3333%
  • INSY7.61+0.02 +0.26%
  • LXRP0.39+0.02 +5.41%
  • MCIG0.1693+0.0018 +1.0746%
  • MJNA0.069-0.002 -2.439%
  • MJNE0.983+0.063 +6.848%
  • MNTR0.811-0.039 -4.588%
  • NDEV0.2899+0.0099 +3.5357%
  • NTRR0.081+0.006 +8.725%
  • OXIS0.063-0.029 -31.522%
  • PMCB0.05665-0.00135 -2.32758%
  • PLPL0.009-0.000 -4.255%
  • RSSFF0.05712-0.00068 -1.17647%
  • SPRWF1.11+0.03 +3.06%
  • SRNA0.1075-0.0010 -0.9217%
  • STEV0.0012+0.0001 +4.3478%
  • TRTC0.1913+0.0008 +0.4199%
  • TURV0.46-0.03 -5.15%
  • TWMJF10.129+0.674 +7.131%
  • XXII2.66-0.02 -0.75%
  • ZDPY0.80+0.02 +2.55%
  • AUDUSD=X0.7819
  • USDJPY=X113.7720
To show stock chart
GWPharmaceuticalsEpidiolexImageKathyYoungAssociatedPressViaTheCannabistDotCo

Race for CBD medication breakthrough: Is pharma firm’s boon the hemp industry’s doom?

Hemp businesses are closely watching as the drug Epidiolex, made by GW Pharmaceuticals, moves through the FDA approval pipeline.

This time next year, an investigational drug hailed as a breakthrough in the science of cannabidiol could be prescribed to children suffering from treatment-resistant epilepsy.

The prospect of its success, however, has caused some unease in the American hemp industry.

London-based GW Pharmaceuticals plc is steering its proprietary Epidiolex oral solution through the U.S. Food and Drug Administration’s approval pipeline.

Read More at TheCannabist.co 



CANNABIS ENTREPRENEURS
READ BLUNT

SIGN UP FOR FREE WEEKLY CANNABIS
BUSINESS NEWS, ANALYSIS AND ALERTS